The myPath Test for Melanoma

Loren Clarke, MD, vice president of Medical Affairs of Dermatology at Myriad Genetics, discusses the company’s new myPath test for melanoma.

Clinical Pearls:

• There are approximately 1.5 million biopsies done in the United States each year for atypical moles in an effort to exclude the possibility of melanoma.
• Approximately 15% of these biopsies are difficult to diagnose.
• The myPath test is objective and produces a single score that can help differentiate malignant melanoma from a benign nevus.